Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia
Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Our overall aim is to determine if the administration of guanfacine in combination with
aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than
any of those medications alone in treating some of the cognitive impairment in schizophrenia.
Phase:
Phase 4
Details
Lead Sponsor:
Research Foundation for Mental Hygiene, Inc.
Collaborators:
Bronx VA Medical Center Icahn School of Medicine at Mount Sinai